PitchBook-人工智能医疗与生命科学风险投资市场快照（英）-2025.1_21页_2mb

报告摘要

AI has evolved through three distinct stages:

Big Data Era (2000s): Focused on predictive analytics, diagnostic tools, and regulated devices like RPM.
AI-Driven Medtech: Advanced imaging analysis, robotic surgery, and genomic diagnostics for earlier, personalized treatment.
Generative AI Era: Enables novel drug design, synthetic data generation, and personalized healthcare delivery, reshaping diagnostics and therapeutics.

Peak in 2021: $22B in 1,018 deals, cooling in 2022/2023, with Q1–Q3 2024 stabilization.
Pre-Market Investment: Late-stage funding dominates, late-stage valuations hit $250M–$400M.
Exit Activity: High in 2020–2021 (IPOs, SPACs, M&A). Moderated post-2021, but recent strong exits suggest a resurgence.

Biotech: AI accelerates drug discovery (computational biology, genomics), clinical trials, and precision medicine.
- Sub-sectors: Small molecules, biologics, gene therapy, cell therapy, nanotech.
Medtech: AI enhances diagnostics (imaging, lab), surgical planning, remote monitoring, and personalized devices.
- Sub-sectors: Diagnostics, imaging, portable care, surgical robotics.
Healthtech: Optimizes administrative workflows, improves clinical documentation (AI scribing), and manages patient care through telemedicine and RPM.
- Sub-sectors: Healthcare IT, chronic disease management, payer analytics.

AI in Diagnostics: Earlier disease detection, personalized imaging, liquid biopsy for cancer, genomics.
Therapeutic Discovery: De novo drug design, predictive modeling for biologics, radiopharmaceuticals.
Healthcare Delivery: Digitized patient monitoring, mental health support via AI chatbots, RPM for chronic disease management.
Efficiency: Streamlined clinical trials, pharmacovigilance, clinical documentation, and administrative workflows.

Commercialization & Integration: Proving clinical efficacy, seamless EHR/Hospital IT integration, long regulatory approval cycles.
Data Infrastructure & Governance: Fragmented data, interoperability issues, ethical concerns, and privacy regulation compliance.
Competition: Big Tech encroachment, price pressures, late-stage consolidation leading to barriers for early startups.
Bias & Liability: AI models must uphold ethical standards, especially in diagnostics and treatment allocation.

Market Maturation: From hype-driven investment to focus on outcomes, clinical validation, and scalability.
Regulatory Hurdles: AI-driven clinical trials/therapies face scrutiny requiring standardization, ethical oversight.
VC Landscape: Investors favor late-stage startups, increasing barriers for early ventures, SPAC influence on exits.

展开完整摘要